Glenmark inks agreement with Astrazeneca by admin- Monday, February 14th, 2022 06:14:17 PM
Glenmark inks settlement with Astrazeneca to commercialize its product Pulmicort Respules in ColumbiaGlenmark Pharmaceuticals, an innovation‐driven, international
pharmaceutical employer, announced that its subsidiary Glenmark Pharmaceuticals Colombia S.A.S. And Astrazeneca Colombia S.A.S. Have entered into an exclusive licensing settlement for the commercialization of Astrazeneca’s drug Pulmicort Respules.
Under the phrases of the settlement, Astrazeneca stays the holder of the registration for Pulmicort Respules and may be answerable for production and providing the drug. Glenmark could be liable for commercialization of Pulmicort Respules in the Colombian marketplace.